Company intelligence / Profile preview

BioNumerik Pharmaceuticals

San Antonio, Texas, United Statessec.gov ↗

Ownership: Private
Employees: ~200
Development stage: Phase 3

Overview

BioNumerik Pharmaceuticals focuses on the discovery and development of oncology drugs. Its lead candidate Tavocept (BNP7787/dimesna) reached Phase III trials for advanced lung adenocarcinoma and small cell carcinoma. Tavocept aims to improve survival and reduce chemotherapy toxicity by targeting thioredoxin/glutaredoxin systems. Another candidate, BNP1350/Karenitecin, was in phase II/III for NSCLC and ovarian cancer but appears discontinued. The company’s pipeline has seen mixed results with some programs discontinued or pending further data.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

karenitecin

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on BioNumerik Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioNumerik Pharmaceuticals.

Explore the full profile